FOLH1 and prostate carcinoma: Previous studies, such as those by Benard et al. and Babich et al., evaluated PSMA-targeted radioligand therapies in nude mouse prostate cancer xenografts, showing tumor reduction and progression delay (Benard et al. 2020; Babich et al. 2020).